ANS and ISN International Society for Neurochemistry, Australia 23-27 Aug 2015
23 Aug 2015 - 31 Dec 2015
People funded by this grant:
Fernandez-Martos C
Project Total: $1,500; Funded by: University of Tasmania - Grant-Conference Support Scheme; University of Tasmania ($1,500).
GRANT
Axon protection in Alzheimer's disease
20 Mar 2015 - 30 Jun 2016
People funded by this grant:
King A,
Canty A,
Fernandez-Martos C
Project Total: $59,097; Alzheimer's disease (AD) affects approximately 11% of the population over 65 years and up to 50% of individuals over 85 years and is now the 3rd major cause of death in Australia. In the absence of effective therapeutic intervention it is imperative that we renew our research efforts along novel and innovative lines to prevent, palliate and/ or reduce this condition. One of the key features of AD is the degeneration of the long nerve processes or axons. These are susceptible to damage and this can result in nervous system disconnection and failure even in the absence of cell loss. My research focuses on understanding why axons degenerate in neurodegenerative disease with the aim of finding effective therapeutic agents to prevent this loss. Due to our lack of mechanistic insight into axon degeneration mechanisms, there are currently no therapeutic drugs that target axon degeneration, and this could be one reason to account for the failure of many therapeutic agents that provide only neuronal protection. Therefore axon protection strategies may offer promise in preventing or delaying the ongoing clinical symptoms of the disease. To address this important issue, I have developed a novel cell culture technique that uses microfluidic technology to separate neuronal axons from the soma. This allows us to probe the cellular mechanisms of axon degeneration in conditions related to AD. Using these novel in vitro techniques I have begun to unravel some of these mechanisms and identify some potential points of intervention. Specifically, I have examined axon degeneration mechanisms following excitotoxicity, which results from overstimulation of neurons. Excitotoxicity is one of the key causes of nerve cell degeneration in AD. My work has shown that excitotoxicity causes axons to degenerate and that destabilization of microtubule proteins is an early event in this degeneration. Importantly, stabilizing microtubules with drugs such as taxol and epothilone D prevents axon degeneration following excitotoxicity in our cell culture model. Taxol and epothilone D are both agents that are currently approved for use in the treatment of cancer. The next step is to test whether these agents can block axon degeneration in animal models. In order to do this I will use two models. Firstly I will use an in vivo model of axon degeneration induced by excitotoxicity. This will be used to directly confirm that microtubule stabilization with epothilone D can protect axons from degeneration following excitotoxicity in vivo. Secondly I will use a mouse model of AD which develops axon pathology and for which excitotoic mechanisms are implicated. This AD will be treated with Epothilone D and pathology examined as well as cognitive function. This project will provide preliminary data to pave the way to expanding the project by obtaining significant funding from national research funding schemes such as NHMRC. Funded by: Equity Trustees Limited - Grant ($59,097); University of Tasmania.
GRANT
Characterization of the physiological effect of neurofilament light subunit (NFL) protein deficiency in Alzheimer's disease pathology: a new therapeutic target for neurodegenerative disease?
1 Jan 2014 - 31 Dec 2014
People funded by this grant:
Fernandez-Martos C
Project Total: $14,500; Funded by: University of Tasmania - Grant-Research Enhancement (REGS); University of Tasmania ($14,500).